Senores Pharmaceuticals Limited — Updates, 09-05-2025: Press Release

Senores Pharmaceuticals has announced a board meeting to discuss the financial results for the quarter and half-year. Its US subsidiary acquired the USFDA-approved ANDA for Tramadol Tablets from APDM Pharmaceuticals, targeting a US market valued at USD 62-119 million. Funded by IPO proceeds, this acquisition expands Senores' portfolio to 61 ANDAs, boosting its presence in complex generics and controlled substances across the US and India manufacturing units. This strategic move enhances Senores’ position in regulated markets.